Page last updated: 2024-08-26

sr141716 and orlistat

sr141716 has been researched along with orlistat in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	40 (72.73)	29.6817
2010's	15 (27.27)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Vastag, B	1
Halford, JC	1
Bérubé-Parent, S; Chaput, JP; Tremblay, A	1
Kennedy, RL; Khoo, EY	1
Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S	1
Cheskin, LJ; Sidhaye, A	1
Blackburn, GL; Waltman, BA	1
Hamann, A	2
Behn, A; Ur, E	1
Halpern, A; Mancini, MC	1
Caterson, ID; Finer, N	1
Cannon, E; Lundquist, LM; Sirimaturos, M	1
Boss, O; Hofbauer, KG; Nicholson, JR	1
Hofbauer, KG; Nicholson, JR	1
Majumdar, SR; Padwal, RS	1
Rotthoff, T; Scherbaum, WA	1
Formiguera, X; Sierra, A	1
Bray, GA; Ryan, DH	1
Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA	1
Zieba, R	1
Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W	1
Bodary, PF; Eitzman, DT; Iglay, HB	1
Kaila, B; Raman, M	1
Nau, JY	1
Al-Zaman, Y; Aylwin, S	1
Aronne, LJ; Neff, LM	1
Barnett, A; Rahim, A; Samat, A	1
Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V	1
Harrison, SA; Kashi, MR; Torres, DM	1
Narbro, K; Neovius, M	1
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U	1
Idelevich, E; Kirch, W; Schindler, C	1
Höcht, C; Mayer, MA; Puyó, A; Taira, CA	1
Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET	1
Kovacs, FE; Szabo, B; Urbanski, MJ	1
DeSantis, SM; Johansson, K; Neovius, K; Neovius, M; Rössner, S	1
Berghold, A; Horvath, K; Jeitler, K; Matyas, E; Pignitter, N; Siebenhofer, A; Siering, U; Stich, AK	1
Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES	1
Cheung, BM; Li, M	1
Amundsen, MO; Berg, C; Engdahl, B; Nordeng, H	1
Fu, L; Liu, C; Ma, L; Ma, Q; Ma, W; Tang, Y; Wang, H	1
Madsbad, S	1
Abrams, K; Ara, R; Cooper, N; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K; Sutton, A; Warren, FC	1
Abrams, K; Ara, R; Blake, L; Cooper, N; Crowther, M; Davies, M; Dunkley, A; Gray, L; Hernández, M; Jackson, R; Khunti, K; Rees, A; Stevenson, M; Sutton, A; Warren, F	1
Bedros, JR; Medvegy, M; Pados, G; Simonyi, G	1
Essawy, S; Zaitone, SA	1
Kautzky-Willer, A; Lemmens-Gruber, R	1
Berghold, A; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A; Siering, U	1
Baretić, M	1
Berghold, A; Horvath, K; Jeitler, K; Meschik, J; Posch, N; Semlitsch, T; Siebenhofer, A	1
Ganesh, S; Rustgi, VK	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T	1

Reviews

40 review(s) available for sr141716 and orlistat

Article	Year
Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Current drug targets, 2004, Volume: 5, Issue:7 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Energy Metabolism; Feeding Behavior; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Topiramate	2004
Obesity and cardiovascular physiology: impact of some pharmacological agents. Current vascular pharmacology, 2005, Volume: 3, Issue:2 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2005
[Drug treatment of obesity]. Ugeskrift for laeger, 2006, Jan-09, Volume: 168, Issue:2 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss	2006
Pharmacologic treatment of obesity. Advances in psychosomatic medicine, 2006, Volume: 27 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate; Zonisamide	2006
Pharmacotherapy to reduce visceral fat. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdominal Fat; Lactones; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2005
[Pharmacotherapy in the treatment of obesity]. MMW Fortschritte der Medizin, 2006, Mar-02, Volume: 148, Issue:9 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Cyclobutanes; Enzyme Inhibitors; Exercise; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2006
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
Pharmacological treatment of obesity. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Energy Metabolism; Homeostasis; Humans; Lactones; Mazindol; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pacific journal of clinical nutrition, 2006, Volume: 15 Suppl Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety; Treatment Outcome	2006
Pharmacologic treatment for obesity. Options for today...and tomorrow. Advance for nurse practitioners, 2006, Volume: 14, Issue:8 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
The obesity epidemic: current and future pharmacological treatments. Annual review of pharmacology and toxicology, 2007, Volume: 47 Topics: Anti-Obesity Agents; Cyclobutanes; Disease Outbreaks; Drug Design; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2007
Pharmacotherapy of obesity. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006, Volume: 114, Issue:9 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Design; Energy Metabolism; Homeostasis; Humans; Lactones; Life Style; Models, Biological; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Technology, Pharmaceutical	2006
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007
[Pharmacotherapy of obesity]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:12 Topics: Anti-Obesity Agents; Anticonvulsants; Cyclobutanes; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Topiramate	2006
[New therapeutic aspects for the control of risk factors in obesity]. Medicina clinica, 2007, Apr-07, Volume: 128, Issue:13 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2007
Drug treatment of the overweight patient. Gastroenterology, 2007, Volume: 132, Issue:6 Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2007
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public health nutrition, 2007, Volume: 10, Issue:10A Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss	2007
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy higieny i medycyny doswiadczalnej (Online), 2007, Oct-19, Volume: 61 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Neurotransmitter Agents; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2007
[Obesity in adults]. Praxis, 2007, Oct-17, Volume: 96, Issue:42 Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2007
Strategies to reduce vascular risk associated with obesity. Current vascular pharmacology, 2007, Volume: 5, Issue:4 Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2007
[Pharmacotherapy of obesity]. Der Internist, 2008, Volume: 49, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2008
Obesity: a review of pathogenesis and management strategies. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:1 Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Exercise; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2008
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide	2008
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms	2007
Pharmacotherapy for obesity in menopausal women. Menopause international, 2008, Volume: 14, Issue:2 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms	2008
Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease, 2008, Volume: 28, Issue:4 Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss	2008
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. International journal of obesity (2005), 2008, Volume: 32, Issue:12 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cost-Benefit Analysis; Cyclobutanes; Europe; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Quality-Adjusted Life Years; Rimonabant; Treatment Outcome; United States	2008
Current pharmacotherapeutic concepts for the treatment of obesity in adults. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Prevalence; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Reduction Behavior; Treatment Outcome; Weight Loss	2009
Recent advances in obesity pharmacotherapy. Current clinical pharmacology, 2009, Volume: 4, Issue:1 Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2009
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult	2009
Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2009, Volume: 10, Issue:5 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Medication Adherence; Odds Ratio; Orlistat; Overweight; Patient Dropouts; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2009
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time; Weight Loss	2009
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2012, Volume: 13, Issue:6 Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2012
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:5 Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Exercise; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Primary Health Care; Pyrazoles; Rimonabant; Risk Reduction Behavior; Treatment Outcome	2012
[The pharmacological treatment of obesity: past, present and future]. Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10 Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones	2012
Obesity and diabetes. Handbook of experimental pharmacology, 2012, Issue:214 Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds	2012
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Weight Loss	2013
Obesity drug therapy. Minerva endocrinologica, 2013, Volume: 38, Issue:3 Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Combinations; Exercise Therapy; Fructose; Gastrointestinal Hormones; Humans; Incretins; Insulin; Insulin Secretion; Intestines; Lactones; Leptin; Life Style; Models, Biological; Neuropeptides; Obesity; Orlistat; Phentermine; Phytotherapy; Piperidines; Plant Preparations; Pyrazoles; Rimonabant; Topiramate	2013
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2016, Mar-02, Volume: 3 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Topiramate; Weight Loss	2016
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in liver disease, 2016, Volume: 20, Issue:2 Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E	2016

Trials

2 trial(s) available for sr141716 and orlistat

Article	Year
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:4 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant	2009
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1 Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss	2017

Article

Year

Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.

Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:4

Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant

2009

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.

BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1

Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss

2017

Other Studies

13 other study(ies) available for sr141716 and orlistat

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Experimental drugs take aim at obesity. JAMA, 2003, Apr-09, Volume: 289, Issue:14 Topics: Animals; Anti-Obesity Agents; Ciliary Neurotrophic Factor; Cyclobutanes; Drug Evaluation; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Recombinant Proteins; Rimonabant; United States; United States Food and Drug Administration	2003
New options for drug treatment of obesity in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 4 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2005
[Antiobesity drugs--new limitations]. Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss	2007
[Pharmacological therapy of obesity]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss	2008
The endocannabinoid system as a target for obesity treatment. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk	2008
Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling. Synapse (New York, N.Y.), 2009, Volume: 63, Issue:8 Topics: Aniline Compounds; Animals; Animals, Newborn; Arachidonic Acids; Benzamides; Bicuculline; Biophysics; Calcium; Calcium Signaling; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Carbamates; Cerebellum; Electric Stimulation; Endocannabinoids; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fluoresceins; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Glycerides; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Lactones; Mice; Muscimol; Orlistat; Patch-Clamp Techniques; Piperidines; Purkinje Cells; Pyrazoles; Quinoxalines; Rimonabant; Signal Transduction; Synapses; Valine	2009
Pharmacotherapy for obesity. British journal of clinical pharmacology, 2009, Volume: 68, Issue:6 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors	2009
Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Anti-Obesity Agents; Child; Cyclobutanes; Databases, Factual; Drug Interactions; Female; Humans; Lactones; Male; Middle Aged; Norway; Orlistat; Piperidines; Practice Patterns, Physicians'; Psychotropic Drugs; Pyrazoles; Rimonabant; Sex Factors; Young Adult	2010
[Simultaneous determination of rimonabant and orlistat illegally added in the weight-loss functional foods by high performance liquid chromatography-tandem mass spectrometry]. Se pu = Chinese journal of chromatography, 2010, Volume: 28, Issue:1 Topics: Chromatography, High Pressure Liquid; Food Analysis; Food Contamination; Functional Food; Humans; Lactones; Orlistat; Piperidines; Pyrazoles; Rimonabant; Tandem Mass Spectrometry	2010
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for laeger, 2011, Feb-21, Volume: 173, Issue:8 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Evidence-Based Medicine; Humans; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Treatment Outcome; Weight Loss	2011
Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats. Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:6 Topics: Adiposity; Animals; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Lactones; Male; Obesity; Orlistat; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Weight Gain	2012